FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2551510118> ?p ?o ?g. }

• W2551510118 abstract "Abstract This prospective multi-center trial (MiniMud) concerns 27 patients (13 females, 14 males - 56 years[18–65]) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) from unrelated donors. The diagnosis and disease status pre-transplant were AML (n=12; 5 CR1, 7 CR2), ALL (n=1; 1 CR2), MM (n=5; 3 PR2,1 PR3, 1 PR4), NHL (n=4; 1 CR1, 2 PR3, 1 PR4), MPS (n=3; 2 stable disease (SD), 1 Relapse), acute RAEB (n=1; 1 progressive disease (PD) and CLL (n=1; 1 PR2). In total, 14 patients were in CR, 9 in PR, 2 in SD, 2 in PD. The median interval between diagnosis and transplant was 27 months [5;171], 24 patients received PBSC and 3 received bone marrow from unrelated 10/10 antigen HLA-identical (high-resolution level). All patients received Fludarabine 30 mg/m2/dx5d, Treosulfan 12 g/m2/dx3d and ATG 2,5 mg/kg/dx3d. After transplant, we observed 2 graft failures, 7 patients developed an AGVHD ≥ grade II (30%). Only 23 patients were eligibile to be analysed after 3 months of follow-up post transplant, 7 patients developed cGVHD (30%) (5 limited and 2 extensive), 12 patients died (7 from TRM causes and 5 from relapse) and 12 patients are alive in CR with a median follow-up of 14 months. Among the global population we defined a low risk subgroup: 17 patients [12 AML (5 CR1, 7 CR2), 1 ALL (CR2), 3 MM (3 PR2) and 1 NHL (CR1)], 2 patients presented an AGVHD ≥ grade II (13%). With a median follow-up of 18 months, 2 patients had a follow-up of less than 3 months, 3 patients developed a cGVHD (20%), 6 patients died (40%) and 9 patients are alive in CR. At one year, the probability of overall survival (OS) and event-free survival (EFS) were 50.4% [32;79], 40% [23;70] for the total population and 60% [37;96], 51.5% [29;90] for the low risk subgroup respectively. To try to demonstrate if Treosulfan allowed a better transplant outcome we performed a paired match-analysis [center and 4 out of 5 other parameters (age, gender, HSC, pre-transplant status and diagnosis] comparing our Treosulfan series and RIC transplants receiving Fludarabine, Busulfan and ATG (2.5–12.5mg/kg) from the SFGM-TC registry. This paired match-analysis found only RICT from related donors in the SFGM-TC database and showed no difference in term of OS and EFS between our unrelated donor-Treosulfan and related donor-SFGM-TC series. Figure Figure Figure Figure In conclusion, these results demonstrate that Treosulfan appears to be a very promising drug that could be included in the conditioning regimen before HSCT from either related or unrelated donors." @default.
• W2551510118 created "2016-11-30" @default.
• W2551510118 creator A5005285747 @default.
• W2551510118 creator A5008084507 @default.
• W2551510118 creator A5022161221 @default.
• W2551510118 creator A5033387273 @default.
• W2551510118 creator A5034473496 @default.
• W2551510118 creator A5045967298 @default.
• W2551510118 creator A5059403965 @default.
• W2551510118 creator A5064531399 @default.
• W2551510118 creator A5068452218 @default.
• W2551510118 creator A5070792872 @default.
• W2551510118 creator A5072027146 @default.
• W2551510118 creator A5072557528 @default.
• W2551510118 creator A5072757261 @default.
• W2551510118 creator A5082189560 @default.
• W2551510118 creator A5087870886 @default.
• W2551510118 date "2007-11-16" @default.
• W2551510118 modified "2023-10-14" @default.
• W2551510118 title "Multi-Center Prospective Trial on Conditioning with Treosulfan, Fludarabine and ATG Before Allogeneic HSCT from Unrelated Donors." @default.
• W2551510118 doi "https://doi.org/10.1182/blood.v110.11.4949.4949" @default.
• W2551510118 hasPublicationYear "2007" @default.
• W2551510118 type Work @default.
• W2551510118 sameAs 2551510118 @default.
• W2551510118 citedByCount "0" @default.
• W2551510118 crossrefType "journal-article" @default.
• W2551510118 hasAuthorship W2551510118A5005285747 @default.
• W2551510118 hasAuthorship W2551510118A5008084507 @default.
• W2551510118 hasAuthorship W2551510118A5022161221 @default.
• W2551510118 hasAuthorship W2551510118A5033387273 @default.
• W2551510118 hasAuthorship W2551510118A5034473496 @default.
• W2551510118 hasAuthorship W2551510118A5045967298 @default.
• W2551510118 hasAuthorship W2551510118A5059403965 @default.
• W2551510118 hasAuthorship W2551510118A5064531399 @default.
• W2551510118 hasAuthorship W2551510118A5068452218 @default.
• W2551510118 hasAuthorship W2551510118A5070792872 @default.
• W2551510118 hasAuthorship W2551510118A5072027146 @default.
• W2551510118 hasAuthorship W2551510118A5072557528 @default.
• W2551510118 hasAuthorship W2551510118A5072757261 @default.
• W2551510118 hasAuthorship W2551510118A5082189560 @default.
• W2551510118 hasAuthorship W2551510118A5087870886 @default.
• W2551510118 hasConcept C126322002 @default.
• W2551510118 hasConcept C141071460 @default.
• W2551510118 hasConcept C2776694085 @default.
• W2551510118 hasConcept C2776755627 @default.
• W2551510118 hasConcept C2777408962 @default.
• W2551510118 hasConcept C2779178397 @default.
• W2551510118 hasConcept C2779263901 @default.
• W2551510118 hasConcept C2780611847 @default.
• W2551510118 hasConcept C2908647359 @default.
• W2551510118 hasConcept C2911091166 @default.
• W2551510118 hasConcept C71924100 @default.
• W2551510118 hasConcept C90924648 @default.
• W2551510118 hasConcept C99454951 @default.
• W2551510118 hasConceptScore W2551510118C126322002 @default.
• W2551510118 hasConceptScore W2551510118C141071460 @default.
• W2551510118 hasConceptScore W2551510118C2776694085 @default.
• W2551510118 hasConceptScore W2551510118C2776755627 @default.
• W2551510118 hasConceptScore W2551510118C2777408962 @default.
• W2551510118 hasConceptScore W2551510118C2779178397 @default.
• W2551510118 hasConceptScore W2551510118C2779263901 @default.
• W2551510118 hasConceptScore W2551510118C2780611847 @default.
• W2551510118 hasConceptScore W2551510118C2908647359 @default.
• W2551510118 hasConceptScore W2551510118C2911091166 @default.
• W2551510118 hasConceptScore W2551510118C71924100 @default.
• W2551510118 hasConceptScore W2551510118C90924648 @default.
• W2551510118 hasConceptScore W2551510118C99454951 @default.
• W2551510118 hasLocation W25515101181 @default.
• W2551510118 hasOpenAccess W2551510118 @default.
• W2551510118 hasPrimaryLocation W25515101181 @default.
• W2551510118 hasRelatedWork W1984641455 @default.
• W2551510118 hasRelatedWork W1998840025 @default.
• W2551510118 hasRelatedWork W2146142127 @default.
• W2551510118 hasRelatedWork W2300788406 @default.
• W2551510118 hasRelatedWork W2583985383 @default.
• W2551510118 hasRelatedWork W2595019264 @default.
• W2551510118 hasRelatedWork W2746112460 @default.
• W2551510118 hasRelatedWork W2769545549 @default.
• W2551510118 hasRelatedWork W2988122511 @default.
• W2551510118 hasRelatedWork W2996223953 @default.
• W2551510118 isParatext "false" @default.
• W2551510118 isRetracted "false" @default.
• W2551510118 magId "2551510118" @default.
• W2551510118 workType "article" @default.